ADVERTISEMENT
Podcasts
Examining Improved Survival, Response Rates Among Patients With Breast Cancer
06/24/2020
Sara Hurvitz, MD, medical oncologist, Ronald Reagan UCLA Medical Center, and Sherene Loi, PhD, senior medical oncologist, Peter MacCallum Cancer Center, discuss their recent study, HER2CLIMB, highlighting the positive findings that include the reduction of intracranial progression and death among patients with breast cancer treated with tucatinib.
Reference:
Lin NU, Murthy RK, Anders CK, et al. Tucatinib versus placebo added to trastuzumab and capecitabine for patients with previously treated HER2+ metastatic breast cancer with brain metastases (HER2CLIMB). J Clin Oncol. 38: 2020 (suppl; abstr 1005). doi: 10.1200/JCO.2020.38.15_suppl.1005
Advertisement
Advertisement
Advertisement
Current Issue
June 2024
Volume 21
Issue 2
Advertisement
Advertisement
What's Trending?
Subscribe to our eNewsletters!
First Report Managed Care Newsletter